Insmed initiated with a Buy at Mizuho

Mizuho analyst Graig Suvannavejh initiated coverage of Insmed with a Buy rating and $28 price target. Insmed markets Arikayce, which he sees having "a potential $1bn+ sales opportunity in orphan lung diseases," pending successful expansion for its indications and geography. The pipeline includes brensocatib in Phase 3 and TPIP in Phase 2, and they also represent "potential $1bn+ opportunities," according to Suvannavejh.